Major League Baseball has long celebrated blockbuster contracts as a sign of ambition, but the recent wave of mega‑deals has produced a string of cautionary tales. Ten of the most lucrative agreements now sit at the center of a debate about risk, performance and fiscal responsibility.
When Big Money Meets Bad Production
The Boston Red Sox expected Masataka Yoshida to be a cornerstone after a four‑year, $115 million deal, yet his .282/.340/.420 line and just 3.3 bWAR over four seasons have fallen far short of expectations. Similarly, Aaron Nola’s $172 million contract with the Philadelphia Phillies has yielded a 6.01 ERA in 2025, a stark decline from his earlier dominance.
Javier Baez’s five‑year stay with the Detroit Tigers produced a sub‑100 wRC+ each season, while Willy Adames’ two‑year stint with the San Francisco Giants delivered a .223 average and 99 wRC+. Marcus Semien, now in New York, has managed only a .594 OPS and two home runs in 40 games, underscoring the volatility of high‑priced infielders.
Manny Machado’s $350 million pact with the San Diego Padres has turned into a .191/.294/.353 slash line in 2026, a performance that has fans questioning the investment. Carlos Correa’s Houston Astros contract, laden with vesting options that could push it to $270 million, adds a layer of financial uncertainty. Rafael Devers, after moving to the Giants, posts a .640 OPS and 74 wRC+, reflecting a continued dip in production.
Anthony Rendon’s seven‑year, $245 million deal with the Los Angeles Angels has been marred by injury, with only 257 games played, while Kris Bryant’s five‑year stay with the Colorado Rockies has been limited to 170 appearances due to persistent health issues.